HERTFORDSHIRE, England and
PITTSBURGH, Feb. 22, 2016 /PRNewswire/ -- Mylan N.V.
(NASDAQ, TASE: MYL) today announced that Mylan CEO Heather Bresch has been elected to serve as
chair of the Generic Pharmaceutical Association's (GPhA) board of
directors. GPhA is an association that represents the world's
leading generic drug manufacturers and suppliers and plays a
critical role in tackling key issues affecting the generics
industry and shaping policies that help ensure patients have access
to high quality, affordable medicines.
Bresch said: "In the decade since serving my last term as chair
of GPhA, the generics industry has evolved significantly within an
increasingly globalized market. Never has there been a greater need
for our association to lead the way in shaping policy that expands
access to high quality generic medicines and biosimilars, which is
why I've committed to return to the role of chair and work with our
industry's leaders to influence positive change to our healthcare
system.
"The value that the generic drug industry brings to the U.S.
healthcare system is indisputable. Today, generic drugs fill 88% of
the prescriptions dispensed in the U.S., but consume only 28% of
the total drug spending. Yet, the harsh reality is that some of the
numerous challenges we currently face could limit patient access to
generic medicine and debilitate our generics industry which serves
as a critical solution to the nation's healthcare challenge.
"In today's political climate, no matter how strong each of us
may be at an individual company level, it's important for us to
stand strongly together with a unified voice for the good of our
shared mission of advancing access to more affordable medicine.
"I would like to recognize GPhA's outgoing board officers
Craig Wheeler, Doug Boothe and the dedicated staff at GPhA for
the critical role they have played to date in continuing to advance
our industry's efforts to improve healthcare in the U.S. I am
energized by the vision and experience GPhA President and CEO
Chip Davis is bringing to further
the association's role in Washington and beyond, and I look forward to
working with the team and our industry's executives in continuing
these efforts."
Bresch's term as chair of GPhA will last for one year.
Previously, she served two one-year terms as the chair of the
association in 2004 and 2005 and two one-year terms as vice chair
in 2003 and 2006.
Mylan is a global pharmaceutical company committed to setting
new standards in healthcare. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 1,400 generic and branded pharmaceuticals,
including antiretroviral therapies on which nearly 50% of people
being treated for HIV/AIDS in the developing world depend. We
market our products in approximately 165 countries and territories.
Our global R&D and manufacturing platform includes more than 50
facilities, and we are one of the world's largest producers of
active pharmaceutical ingredients. Every member of our nearly
35,000-strong workforce is dedicated to creating better health for
a better world, one person at a time. Learn more at mylan.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mylan-ceo-heather-bresch-elected-chair-of-generic-pharmaceutical-association-300224192.html
SOURCE Mylan N.V.